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Abstract
Recently, the use of nebulized antibiotics in the intensive
care unit, in particular amikacin, has been the subject of
much discussion, owing to unconvincing results from the
latest randomized clinical trials. Here, we examine and
reappraise the evidence in favor and against this
therapeutic strategy; we then discuss the potential factors
that might have played a role in the negative findings of
recent clinical trials. Also, we call attention to several
factors that are seldom considered by study developers
and regulatory agencies, to promote translational
research in this field and improve the design of future
randomized clinical trials.
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In light of the latest negative results from large random-
ized clinical trials, i.e., the IASIS [1] and the INHALE II
trials [2], evaluating the efficacy of inhaled amikacin in
critically ill mechanically ventilated patients, scientists are
calling into question the merits of the use of inhaled anti-
biotics in the field of critical care medicine. In this review
we elaborate on some of the most cogent reasons for con-
tinuing investigating the merits of inhaled antibiotics, and
we extrapolate from the latest undesirable findings. Fur-
thermore, we provide our perspective on the next poten-
tial targets, in both clinical and laboratory research.
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The therapeutic promise of inhaled amikacin
Severe respiratory infections developed in hospital settings,
i.e., hospital-acquired pneumonia (HAP) and ventilator-
associated pneumonia (VAP), are common [3] and consti-
tute a significant burden for healthcare systems. VAP, which
is commonly caused by aerobic Gram-negative bacilli [6],
prolongs hospitalization [4] and consequently increases hos-
pital costs [5].
In hospital settings, multi-drug resistant (MDR) path-
ogens are prevalent, which makes choosing the most
appropriate empiric therapy extremely challenging. The
latest American [3] and European guidelines [7] for the
management of HAP/VAP patients provided recom-
mendations to tackle this problem. Yet, according to
their suggestions, in settings with high levels of anti-
biotic resistance, the use of narrow-spectrum empiric
antibiotics is impractical, creating a vicious cycle that
could even sustain MDR. Furthermore, applicability of
clinical practice guidelines is uncertain in countries de-
fined by the highest prevalence of pandrug resistant
(PDR) pathogens and widespread use of antibiotics. As
a result, in upcoming years, nosocomial MDR is ex-
pected to rise globally.
Bearing in mind this threatening scenario, the inherent
limitations of intravenous antibiotics for the treatment of
pulmonary infections should be emphasized. Indeed,
intravenous antibiotics often present insufficient pulmon-
ary distribution [8]. Laboratory evidence has also consist-
ently confirmed marginal concentrations of antibiotics in
bacterial biofilm retained into endotracheal tubes [9].
Additionally, intravenous antibiotics are often under-
dosed in patients with a sepsis-related hyper-dynamic
state or larger distribution volumes for vast edema [10].
These factors intensify the selective pressure for the devel-
opment and worsening of MDR. In theory, administration
of nebulized antibiotics is a potential therapeutic alternative
[11] to overcome these limitations. Nebulized antibiotics
could deliver an effective amount of the drugs directly into
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the respiratory system, overcoming minimal inhibitory con-
centrations (MICs), while thwarting selective pressure and
MDR development [12]. Additionally, systemic exposure to
antibiotics and adverse effects could be reduced. Among
the available antibiotics that could be nebulized into the re-
spiratory system, aminoglycosides have drawn much atten-
tion, since they are concentration-dependent antibiotics
with post-antibiotic effect and present a broad spectrum of
activity. Aminoglycosides have been already applied as
chronic therapies for cystic fibrosis patients with difficult-
to-treat infections [13]. In critically ill patients, nebulized
amikacin could attain substantial pulmonary concentra-
tions, and achieve outstanding bactericidal efficacy. More-
over, nephrotoxicity and ototoxicity, which are commonly
associated with intravenous administration of amikacin,
could be curtailed.
A number of laboratory and clinical studies have cor-
roborated the merits of inhaled amikacin in VAP. In an
animal study, Goldstein and collaborators [14] adminis-
tered 45 mg/kg nebulized amikacin in pigs with Escheichia
coli severe pneumonia. Amikacin concentration in the
most severely infected pulmonary regions averaged 40 ±
65 μg/g, achieving tissue concentrations 30 times higher
than intravenous amikacin. In a pivotal study by Lu et al.
[15], 40 patients with Pseudomonas aeruginosa VAP were
included in a randomized study. Twenty patients with sus-
ceptible or intermediate strains received nebulized ceftazi-
dime and amikacin, whereas 17 patients infected with
susceptible strains only received intravenous ceftazidime
and amikacin. After 8 days, the curative rate was similar
between groups, yet only in the intravenous group did
antibiotic resistance develop. In a later study, Niederman
et al. [16] studied 69 mechanically ventilated patients with
Gram-negative VAP receiving nebulized amikacin with
systemic antibiotics. They found that amikacin distributed
well throughout the lung parenchyma, with very high tra-
cheal and alveolar levels, while maintaining intravenous
concentrations below the renal toxicity threshold. Those
patients who received amikacin required significantly less
systemic antibiotics than those who were given placebo. A
recent meta-analysis [17] and a consensus guideline [18]
took a closer look into the use of nebulized antibiotics. In
particular, in the meta-analysis, Solé-Lleonart and collabo-
rators [17] evaluated the effects of nebulized aminoglyco-
sides or colistin, harnessed as adjunctive or substitutive
therapies. The authors identified 11 studies, six of which
were randomized trials, which were biased by methodo-
logical heterogeneity and limitations. The authors found
that nebulized antibiotics in VAP patients reduced emer-
gence of MDR, and clinical resolution was more frequent,
specifically in VAP cases caused by resistant pathogens.
Yet nebulized antibiotics increased the rate of respiratory
complications, in particular hypoxemia after the nebuliza-
tion, obstruction of the expiratory filter, and increase in
peak airway pressure. In the consensus guideline by Rello
and collaborators [18] this meta-analysis was acknowl-
edged and the global use of nebulized antibiotics in
units challenged by highly resistant pathogens. Ultim-
ately, they advised against the use of nebulized antibi-
otics in VAP, primarily owing to the marginal scientific
evidence.
Recent disappointing results
The randomized trial of amikacin/fosfomycin inhalation
system for the adjunctive therapy of Gram-negative ventila-
tor associated pneumonia (IASIS Trial) [1] recently evalu-
ated nebulized amikacin/fosfomycin as an adjunctive
therapy for the treatment of Gram-negative bacterial VAP.
A similar study of the inhaled amikacin solution (BAY 41–
6551) as adjunctive therapy in the treatment of Gram-
negative pneumonia (INHALE I and II program) has re-
cently been completed (ClinicalTrials.gov identifiers NCT
0179993 and NCT00805168). Turning first to the trial by
Kollef and collaborators [1], this was a phase 2, multicenter,
double-blind trial. More than 140 patients with VAP re-
ceived intravenous meropenem or imipenem, and either a
combination of nebulized antibiotics (300 mg amikacin and
120 mg fosfomycin), twice daily for up to 10 days, or nebu-
lized placebo. This study was preceded by various phase I
studies [19–21], confirming that the combination of antibi-
otics, delivered through the PARI eflow system (PARI
GmbH, Germany), achieved very high tracheal aspirate con-
centrations and low systemic absorption. The primary out-
come was variation in the clinical pulmonary infection
score (CPIS) [22]—adjusted per baseline values—during the
planned 10-day treatment period. Remarkable tracheal se-
cretion concentrations of amikacin and fosfomycin were
achieved during nebulization, higher than 7000 and 2000
mg/mL, respectively. Tracheal secretion colonization by
Gram-negative pathogens also decreased in the treatment
group, yet the study failed to demonstrate any benefit on
CPIS variations, clinical cure rates, ventilator-and ICU-free
days, and mortality. As for the recently completed INHALE
program, 725 patients with Gram-negative VAP were ran-
domized to receive standard intravenous therapy and either
400 mg of nebulized amikacin every 12 h for 10 days or
nebulized placebo. In this study, amikacin was nebulized
through an inhalation system synchronized with the inspira-
tory phase, as detailed in previous publications [23, 24]. Un-
fortunately, on November 24th 2017, the main study
promoter announced that inhaled amikacin did not demon-
strate superiority over standard of care and nebulized pla-
cebo in the main endpoint [2]. Moreover, secondary
outcomes did not favor the use of inhaled amikacin, includ-
ing pneumonia-related mortality, early clinical response,
number of days on mechanical ventilation, and number of
ICU days.
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Reappraisal of the latest clinical results and the
next research chapter
The results of the aforementioned latest studies are quite
discouraging, particularly at the moment, when only lim-
ited efforts are being made to develop novel antibiotics.
Nevertheless, we believe that many factors could have
contributed to this lack of positive outcomes and in the
following paragraphs we will provide our point of view.
On the one hand, the delivery of nebulized antibiotics
into the distal portion of highly infected pulmonary re-
gions filled with respiratory secretions seems just imprac-
tical (Fig. 1), irrespective of the best currently available
nebulizers. Recent reports [25] have emphasized that even
in healthy patients, only a limited amount of the nebulized
dose is delivered into the lungs, predominantly in the
proximal regions. Irrespective of the challenges encoun-
tered, several reports in VAP patients demonstrated very
high concentrations in the epithelial lining fluid (ELF) [23]
and tracheal aspirates [16], using the device described in
the INHALE program.
We would like to point out several factors that may have
been underestimated in aforementioned trials but which
play a critical role in lung deposition of nebulized antibi-
otics during mechanical ventilation. Firstly, the extension
and severity of lung infections critically affect lung distri-
bution of nebulized antibiotics. Indeed, sufficient airway
patency and alveolar opening are required to deposit anti-
biotics on the affected areas. In an interesting study [26]
in pigs with pneumonia, lung tissue concentrations of
nebulized antibiotics were significantly higher in pulmon-
ary segments with early stages of lung infection than in
segments with confluent pneumonia and lung abscess.
The IASIS and INHALE II trials often started nebulization
days after clinical diagnosis. Considering that VAP diagno-
sis is challenging and time-consuming, it is conceivable
that many patients already presented consolidated pul-
monary regions upon the first nebulization.
Secondly, both studies used vibrating mesh nebulizers. It
is estimated that these devices increase the efficiency of
aerosol delivery to 40–60% [27, 28]. However, there seem
to be incongruities between the achieved antibiotic concen-
trations [16, 21, 24], the bactericidal effects corroborated by
animal studies [15, 29], and the lack of clear benefits in
phase III trials. In respect of the animal studies, one of the
main limitations is that often the models do not fully re-
semble the complexity of patients admitted into an ICU
and who develop VAP after a few days of intubation. For
instance, animal studies are conducted in healthy young
pigs without chronic pulmonary diseases. In addition, nebu-
lization of antibiotics in these pre-clinical experiments initi-
ates immediately upon development of pneumonia, which
is difficult to reproduce in clinical settings.
Thirdly, it is well acknowledged that the mass median
aerodynamic diameter (MMAD) should range between 1
and 5 μm to reach distal airways and alveoli [30, 31]. Hu-
midification affects lung deposition of nebulized antibiotics
[30, 31], because controlled in vitro studies demonstrated
that conditioning inspiratory gases lead to an increase in
Fig. 1 Bronchoscopic evaluation of mechanically ventilated Large White Landrace pigs challenged by Pseudomonas aeruginosa. a Main right
upper bronchus, prior to bacterial challenge; of note no abnormalities can be found. b After 24 h from inoculation of 15 mL of 107 colony
forming units of P. aeruginosa, the distal portion of the right middle bronchus is copiously filled with purulent secretions with a reduction of the
distal bronchi by more than 60%. c Main right medium bronchus, prior to bacterial challenge, with no abnormalities. d After 24 h from
inoculation of 15 mL of 107 colony forming units of P. aeruginosa, the bronchial mucosa is highly hyperemic and retained purulent secretions are
evident throughout the bronchus, almost completely obstructing distal bronchi
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MMAD [32] and, potentially, to deposition on endotracheal
tube and ventilator circuits [33]. In the IASIS and INHALE
II trials, humidification was maintained throughout nebuli-
zation, so as to slightly increase the MMAD. Nonetheless,
considering that ICU patients with pneumonia have hetero-
geneous requirements with regard to the level of ventilatory
assistance, and the performance of humidification systems
may vary [34, 35], any inference derived from highly con-
trolled in vitro environments might be difficult to reproduce
in clinical settings. Following the same line of thought, air-
flow turbulence should be avoided during nebulization [36].
Some investigators suggest that ventilatory parameters
should be adjusted, i.e., using volume-control mode, con-
stant inspiratory flow [37], and low minute ventilation and
respiratory frequency. Furthermore, an inspiratory-to-
expiratory ratio ≤ 50% and an end-inspiratory pause repre-
senting 20% of the duty cycle should be used to provide
enough time for aerosol sedimentation in the alveolar space
[38]. These recommendations are difficult to apply in busy,
understaffed units, and which may lack expertise in respira-
tory management. Therefore, in the latest clinical trials, in-
vestigators prioritized straightforward administration of
nebulized antibiotics, avoiding challenging ventilatory ad-
justments. This may have resulted in an unpredictable deliv-
ery of the dosed antibiotic, specifically in patients requiring
high minute ventilation, on pressure-control ventilation, or
ventilated with shorter inspiratory time.
Finally, we would like to raise our concerns regarding the
potential methodological biases in the design of these latest
clinical studies. The IASIS and INHALE II trials were
intended to demonstrate superiority in clinical outcomes
such as change in CPIS or mortality. These outcomes were
fully endorsed by the American Food and Drug Adminis-
tration agency, though from a research and clinical stand-
point, the reliability of these parameters is questionable. For
instance, the CPIS was originally designed to diagnose VAP
[22], rather than to evaluate the response to treatment,
whereas survival is an outcome not closely related to VAP,
difficult to achieve in severely critically ill patients, and can
also be biased due to variations in standards of treatment
between countries or clinical departments. In addition,
many experts in this field would argue that the use of
nebulized antibiotics could have merits in patients with
difficult-to-treat infections, e.g., caused by MDR, extensively
drug-resistant (XDR) or even PDR pathogens. Theoretic-
ally, the inclusion of a large proportion of these patients
would certainly have helped in detecting positive outcomes
and would have highlighted the most appropriate clinical
indication of this therapeutic strategy.
Considering the above arguments, we would like to
present a few thought-provoking ideas to point toward
new directions for proficient research. Turning first to
the pre-clinical trials, it would be ideal to conduct com-
prehensive studies in larger animals before designing
clinical studies. In particular, animal studies could
elucidate key microbiology and pharmacology factors
impossible to obtain in ICU patients, by means of post-
mortem analysis of pulmonary tissue [39]. Moreover,
lung deposition could be accurately measured in these
models through inhalation of radio-labeled tracers
tracked by gamma scintigraphy or positron emission
tomography [40].
Secondly, although investigators have tried to achieve
the highest pulmonary concentrations of nebulized anti-
biotics, we call attention to the risks of pulmonary injury
associated with these drugs, specifically in lungs already
damaged by a primary infectious-related insult. With
this in mind, future animal studies should also evaluate
the pulmonary effects of these antibiotics, while at the
same time achieving the highest concentrations.
Thirdly, considering pathogenesis of VAP and the po-
tential for mucus retention and alveolar collapse, future
investigations should look into the optimal timing to initi-
ate nebulization of antibiotics. Likewise, in future random-
ized trials, earlier treatments should be given preference.
Fourthly, based on the latest negative findings, the long-
standing optimistic view that ventilatory settings should not
be adjusted to optimize delivery of nebulized antibiotics
seems implausible, and should be reappraised in future
studies. Additionally, most of the evidence on the effects of
ventilatory settings and humidification on deposition of
nebulized antibiotics seems outdated, relying on studies
that used earlier generations of nebulizers. Consequently,
larger efforts should be made to validate performance of
novel technology, testing a large variety of settings in reli-
able models of critically ill ventilated patients.
Finally, we are firmly convinced that nebulized antibi-
otics should be primarily applied against pathogens virtu-
ally untreatable through standard intravenous treatment.
To this end, patients with MDR, XDR, and PDR pulmon-
ary infections should be the primary focus in future stud-
ies. Additionally, given the promising results [12] of the
effects of nebulized antibiotics as a preventive strategy for
drug resistance, we are inclined to believe that it would be
reasonable, in the era of MDR, to redirect the goals of this
promising therapy toward the prevention of selective pres-
sure and avoidance of MDR development.
Conclusions
Irrespective of the most recent unsuccessful findings, we
believe that nebulized amikacin for severe pulmonary in-
fections still offers promising prospects in the ICU.
Nevertheless, several methodological and technical chal-
lenges need to be overcome before embracing this thera-
peutic strategy. We call for a substantial body of future
basic and clinical research to further investigate the
principles of pulmonary nebulization during mechanical
ventilation and to validate efficacy and safety of the most
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innovative nebulizers, and, last but not least, we call for
clinical studies testing feasible and reliable outcomes to
ultimately decide whether nebulized amikacin should be
applied—and to whom.
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